Botulinum toxin B reduces sialorrhea in parkinsonism

被引:41
作者
Racette, BA
Good, L
Sagitto, S
Perlmutter, JS
机构
[1] Washington Univ, Sch Med, Dept Neurol & Neurol Surg, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Amer Parkinson Dis Assoc Adv Ctr Parkinson Res, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Huntington Dis Soc Amer Ctr Excellence, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA
关键词
botulinum toxin B; parkinsonism; sialorrhea;
D O I
10.1002/mds.10484
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We report on our open-label experience with botulinum toxin B for the treatment of severe sialorrhea associated with parkinsonism. Nine adult patients with parkinsonism and medically intractable sialorrhea were treated with botulinum toxin B (1,000 units into each parotid gland using superficial landmarks). After treatment, patients experienced a 61% mean subjective improvement and a 42% mean reduction of quantitative saliva production. There were no adverse effects seen in any subjects. Mean peak benefit from injections lasted 14 weeks. We conclude that denervation of salivary glands with botulinum toxin B produces excellent reduction of excessive salivation associated with parkinsonism. (C) 2003 Movement Disorder Society.
引用
收藏
页码:1059 / 1061
页数:3
相关论文
共 16 条
[1]   Botulinum toxin is a useful treatment in excessive drooling of saliva [J].
Bhatia, KP ;
Münchau, A ;
Brown, P .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (05) :697-697
[2]   Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia [J].
Brashear, A ;
Lew, MF ;
Dykstra, DD ;
Comella, CL ;
Factor, SA ;
Rodnitzky, RL ;
Trosch, R ;
Singer, C ;
Brin, MF ;
Murray, JJ ;
Wallace, JD ;
Willmer-Hulme, A ;
Koller, M .
NEUROLOGY, 1999, 53 (07) :1439-1446
[3]   Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia [J].
Brin, MF ;
Lew, MF ;
Adler, CH ;
Comella, CL ;
Factor, SA ;
Jankovic, J ;
O'Brien, C ;
Murray, JJ ;
Wallace, JD ;
Willmer-Hulme, A ;
Koller, M .
NEUROLOGY, 1999, 53 (07) :1431-1438
[4]  
EADIE MJ, 1965, AUSTRALAS ANN MED, V14, P13
[5]   Botulinum toxin to reduce saliva flow: Selected indications for ultrasound-guided toxin application into salivary glands [J].
Ellies, M ;
Laskawi, R ;
Rohrbach-Volland, S ;
Arglebe, C ;
Beuche, W .
LARYNGOSCOPE, 2002, 112 (01) :82-86
[6]  
JANKOVIC J, 1987, NEUROLOGY, V30, P1326
[7]   Botulinum toxin A:: a new option for treatment of drooling in children with cerebral palsy.: Presentation of a case series [J].
Jongerius, PH ;
Rotteveel, JJ ;
van den Hoogen, F ;
Joosten, F ;
van Hulst, K ;
Gabreëls, FJM .
EUROPEAN JOURNAL OF PEDIATRICS, 2001, 160 (08) :509-512
[8]  
Jost WH, 1999, MOVEMENT DISORD, V14, P1057, DOI 10.1002/1531-8257(199911)14:6<1057::AID-MDS1033>3.0.CO
[9]  
2-4
[10]   Treatment of sialorrhea with glycopyrrolate - A double-blind, dose-ranging study [J].
Mier, RJ ;
Bachrach, SJ ;
Lakin, RC ;
Barker, T ;
Childs, J ;
Moran, M .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2000, 154 (12) :1214-1218